A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer
NCT ID: NCT01836120
Last Updated: 2013-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
100 participants
INTERVENTIONAL
2013-04-30
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer
NCT03137004
Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma
NCT03083613
Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study
NCT02555358
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
NCT06296706
Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer
NCT02072317
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Raltitrexed plus Docetaxel
Raltitrexed plus Docetaxel
Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d
1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)
Docetaxel
Docetaxel
Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Raltitrexed plus Docetaxel
Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d
1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)
Docetaxel
Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2;
3. Histologically or cytologically confirmed gastric cancer;
4. The first-line chemotherapy failure (required containing 5-fluorouracil)
5. At least have one measurable disease(according to RECIST, Response Evaluation Criteria in Solid Tumors )
6. Life expectancy of at least 3 months;
Exclusion Criteria
2. Active or uncontrolled infection;
3. Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial;
4. Pregnant or lactating women.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hebei Tumor Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hebei Tumor Hospital
Shijiazhuang, Hebei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HBTH103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.